At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA): A Phase II, Prospective, Double-Blind Study
In Brief
A Phase 2 clinical trial evaluating Dapagliflozin and Placebo for Heart Failure With Preserved Ejection Fraction. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and improve cardiac metabolism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartFeb 2021
Primary CompletionNov 2022
TodayJul 2026
First PostedJan 29, 2021
Enrollment StartFeb 24, 2021
Primary CompletionNov 17, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.4 years ago
Interventions
Dapagliflozindrug
10 mg orally once a day
Placebodrug
Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient